Angarus Therapeutics Overview

  • Founded
  • 2018
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Investors
  • 1

Angarus Therapeutics General Information

Description

Developer of immuno-oncology therapies intended to respond to the urgent needs of cancer treatment. The company is engaged in developing checkpoint blockers on the innate immunity STING pathway, with a preclinical data demonstrating that a combination of checkpoint blockers, both innate and adaptive, leads to long term survival, thereby providing patients with wide-range of cancer type treatments.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 428 Oakmead Parkway
  • Sunnyvale, CA 94085
  • United States
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Angarus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 15-May-2020 Completed Pre-Clinical Trials
To view Angarus Therapeutics’s complete valuation and funding history, request access »

Angarus Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Nigel Ray Chief Executive Officer and President
Chih-Ping Liu Ph.D Co-Founder, Managing Director and Executive Chairman of the Board of Directors
Lingyin Li Ph.D Scientific Co-Founder and Member of Scientific Advisory Board
Mark Smith Ph.D Scientific Co-Founder
To view Angarus Therapeutics’s complete executive team members history, request access »

Angarus Therapeutics Board Members (1)

Name Representing Role Since
Chih-Ping Liu Ph.D Angarus Therapeutics Co-Founder, Managing Director and Executive Chairman of the Board of Directors 000 0000
To view Angarus Therapeutics’s complete board members history, request access »

Angarus Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Tsingyuan Ventures Venture Capital Minority 000 0000 000000 0
To view Angarus Therapeutics’s complete investors history, request access »